International Journal of Academic Health and Medical Research (IJAHMR)
ISSN: 2643-9824
Vol. 9 Issue 9 September - 2025, Pages: 13-16

Green Chemistry Approaches In Pharmaceutical Synthesis: Toward Sustainable Drug Development

Ahmed Attahiru

Department of Pure and Industrial Chemistry, Faculty of Physical Sciences
Kebbi State University of Science and Technology, Aliero
Kebbi State, Nigeria
E-mail address: a.attahiru0101@gmail.com
ORCID ID: https://orcid.org/0009-0009-3437-2287

ABSTRACT: *The demand for sustainable pharmaceutical development has intensified in recent decades, owing to the environmental, economic, and regulatory challenges associated with conventional drug synthesis. Green chemistry offers a guiding framework for designing processes that minimize waste, reduce toxicity, improve atom economy, and utilize renewable feedstocks. The integration of these principles in pharmaceutical sciences has the potential to transform how drugs are discovered, synthesized, and manufactured, aligning innovation with global sustainability goals. This review critically examines advances in green chemistry approaches for pharmaceutical synthesis, with a focus on catalytic strategies, solvent innovations, continuous-flow processing, renewable feedstock utilization, and computational design. Case studies of drugs produced through green routes highlight practical applications and benefits, while an evaluation of challenges and limitations underscores areas requiring further attention. Methodology for this review included a systematic literature search from 2015 to 2025 across databases such as PubMed, Scopus, and Web of Science. Peer-reviewed studies, patents, and regulatory documents were analyzed thematically to synthesize emerging trends and opportunities. Findings reveal that catalysis, continuous-flow technologies, and biocatalysis are among the most promising drivers of green transformation in drug synthesis. Regulatory perspectives, policy frameworks, and future prospects are also discussed, highlighting the role of digital tools and artificial intelligence in advancing sustainable drug development. The review concludes that embedding green chemistry principles into pharmaceutical synthesis not only benefits the environment but also enhances process efficiency, cost-effectiveness, and patient safety, paving the way for sustainable innovation in global healthcare.*

Keywords: Green chemistry, Pharmaceutical synthesis, Sustainable drug development, Catalysis, Continuous flow, Renewable feedstocks

1. INTRODUCTION

Pharmaceutical synthesis has historically relied on processes that are resource-intensive, environmentally hazardous, and economically costly. Large amounts of solvents, energy, and reagents are consumed in drug manufacturing, generating substantial waste streams. It has been estimated that the pharmaceutical sector produces 55% more greenhouse gas emissions per dollar of revenue than the automotive industry (Winterton, 2021). Such statistics underscore the urgency of adopting cleaner, safer, and more sustainable alternatives.

Green chemistry, first defined by Anastas and Warner in the 1990s, is "the design of chemical products and processes that reduce or eliminate the use and generation of hazardous substances" (Anastas & Eghbali, 2018). Its twelve principles emphasize waste prevention, atom economy, safer solvents, catalysis, renewable feedstocks, energy efficiency, and product degradability. These principles provide a roadmap for aligning chemical innovation with environmental stewardship.

Within pharmaceuticals, the implications of green chemistry are profound. Drug development pipelines are often lengthy, expensive, and environmentally intensive. By redesigning synthetic routes to improve atom economy and reduce hazardous waste, pharmaceutical companies can lower costs, meet regulatory requirements, and enhance sustainability performance (Jiménez-González et al., 2019). Moreover, the rising demand for personalized medicine and biologics requires flexible and adaptive manufacturing systems, where green chemistry offers practical solutions.

Recent years have witnessed remarkable progress in integrating green chemistry into drug development. Advances include transition-metal catalysis, biocatalysis, solvent substitution, continuous flow technologies, and renewable biomass utilization. Computational chemistry and artificial intelligence (AI) now play a key role in designing efficient synthetic routes and predicting environmental impacts (Li & Trost, 2020). Several landmark drugs, including atorvastatin, sitagliptin, and artemisinin, have been synthesized through greener routes, demonstrating industrial feasibility.

This review aims to comprehensively evaluate the progress and prospects of green chemistry approaches in pharmaceutical synthesis. By examining catalytic methods, solvent innovations, continuous-flow chemistry, renewable feedstocks, and computational tools, this paper highlights the transformative role of green chemistry in sustainable drug development.

2. METHODOLOGY

The methodology for this review was structured to ensure coverage of the most relevant and up to date sources in green pharmaceutical synthesis.

2.1 Literature Search

A systematic search was conducted in PubMed, Scopus, Web of Science, and Google Scholar between January 2015 and March 2025. Keywords included "green chemistry in pharmaceuticals," "sustainable drug synthesis," "biocatalysis in drug development," "continuous flow chemistry pharmaceuticals," "green solvents," and "renewable feedstocks pharmaceuticals."

2.2 Inclusion and Exclusion Criteria

- **Inclusion:** Peer-reviewed journal articles, systematic reviews, patents, and regulatory documents published from 2015–2025; case studies of drug development using green approaches; and English-language publications.
- **Exclusion:** Non-English sources, studies unrelated to pharmaceutical synthesis, articles published before 2015 (except for foundational works such as Anastas & Warner's principles).

2.3 Data Extraction and Analysis

The retrieved literature was categorized into thematic domains: catalytic strategies, green solvents, continuous flow technologies, renewable feedstocks, computational design, case studies, challenges, and regulatory perspectives. Each domain was critically analyzed to identify trends, benefits, limitations, and opportunities.

3. PRINCIPLES OF GREEN CHEMISTRY IN PHARMACEUTICAL SYNTHESIS

Green chemistry is guided by twelve principles, several of which are particularly critical for pharmaceuticals. For example, atom economy emphasizes maximizing the incorporation of all reactants into the final product, which reduces waste and cost (Li & Trost, 2020). Prevention of waste generation is more sustainable than managing waste after it is formed, making it essential for pharmaceutical manufacturing (Anastas & Eghbali, 2018).

Other relevant principles include:

- **Safer solvents:** Substitution of toxic organic solvents with benign alternatives such as supercritical CO_2, water, or deep eutectic solvents (Poliakoff et al., 2019).
- **Catalysis:** The use of selective catalysts to enhance yields under milder conditions, replacing stoichiometric reagents (Kumar & Singh, 2021).
- **Renewable feedstocks:** Incorporation of bio-based precursors such as sugars, lignin, and fatty acids in drug synthesis (Calarco et al., 2020).
- **Design for degradation:** Creating pharmaceuticals that degrade into harmless products at the end of their life cycle, minimizing environmental persistence.

Generally, these principles shift pharmaceutical synthesis from a linear "take-make-dispose" model to a more circular and sustainable paradigm.

4. ADVANCES IN CATALYSIS

Catalysis is at the heart of green chemistry, enabling transformations that are selective, efficient, and environmentally benign.

4.1 Transition Metal Catalysis

Transition metals such as palladium, nickel, and ruthenium play critical roles in modern drug synthesis. Cross-coupling and C–H activation strategies reduce the need for pre-functionalized reagents, improving atom economy (Andraos, 2021). Pharmaceutical companies have successfully applied such methods to shorten synthetic routes for active pharmaceutical ingredients (APIs).

4.2 Biocatalysis

Biocatalysis has gained prominence in pharmaceutical synthesis, leveraging enzymes to achieve stereoselective transformations under mild conditions (Kumar & Singh, 2021). For instance, Merck developed a biocatalytic route for sitagliptin using a transaminase, replacing a rhodium-catalyzed hydrogenation. The new process improved yield, reduced waste, and eliminated precious metal use (Tao et al., 2019). Directed evolution techniques have expanded the range and robustness of biocatalysts, enabling broader industrial application.

4.3 Organocatalysis

Organocatalysis employs small organic molecules as catalysts, eliminating dependence on metals. Organocatalytic strategies have been successfully applied in the asymmetric synthesis of pharmaceuticals, offering scalability and cost-effectiveness (Anastas & Eghbali, 2018).

These catalytic innovations significantly reduce waste, improve efficiency, and enhance sustainability in pharmaceutical synthesis.

5. GREEN SOLVENT SYSTEMS

Solvents account for up to 80% of materials used in pharmaceutical synthesis, making them a major contributor to environmental impact (Poliakoff et al., 2019).

- **Supercritical CO_2 ($scCO_2$):** Widely applied in hydrogenation and extraction, $scCO_2$ is non-toxic, recyclable, and reduces volatile organic compound emissions.
- **Ionic Liquids (ILs):** Non-volatile and tunable, ILs replace volatile organic solvents but concerns about biodegradability remain (Winterton, 2021).

- **Deep Eutectic Solvents (DES):** Formed from safe components like choline chloride, DES offer biodegradability and cost-effectiveness (Calarco et al., 2020).
- **Water:** As a universal solvent, water is particularly effective in biocatalysis, reducing toxicity and cost (Tao et al., 2019).

The transition toward greener solvent systems align with the principle of designing safer chemical processes and reducing environmental toxicity.

6. CONTINUOUS FLOW CHEMISTRY

Continuous flow chemistry has emerged as a transformative alternative to batch processing in pharmaceuticals.

Advantages include improved heat and mass transfer, precise control of reaction conditions, and scalability (Klapars & Jensen, 2022). Flow systems enhance safety for hazardous reactions such as nitrations and hydrogenations. They also allow multistep synthesis in a single integrated process, reducing energy use and waste.

Industrial case studies highlight applications in the synthesis of oncology drugs, antivirals, and antibiotics, demonstrating industrial feasibility and regulatory acceptance (Gawande et al., 2020).

7. RENEWABLE FEEDSTOCKS AND BIOMASS UTILIZATION

The reliance on petroleum-based feedstocks remains a barrier to sustainability in pharmaceuticals. Renewable feedstocks, including lignocellulosic biomass, sugars, and plant oils, are increasingly explored as alternatives.

For example, artemisinin, a key antimalarial drug, is now semi-synthetically produced using engineered yeast to generate artemisinic acid (Calarco et al., 2020). This approach stabilizes supply and reduces dependence on agricultural production. Similarly, fatty acids from vegetable oils are being used as precursors for drug intermediates.

Renewable feedstocks not only reduce environmental impact but also enhance supply chain resilience.

8. COMPUTATIONAL AND DIGITAL APPROACHES

Digital tools are becoming indispensable in green pharmaceutical synthesis. Retrosynthetic software powered by AI can propose efficient synthetic routes with better atom economy and reduced waste (Li & Trost, 2020). Machine learning models predict solvent toxicity, catalyst performance, and environmental impacts, guiding sustainable choices (Andraos, 2021).

Digital twins, virtual replicas of manufacturing processes, allow real-time monitoring and optimization, enhancing efficiency and reducing resource consumption (Jiménez-González et al., 2019).

9. CASE STUDIES IN GREEN PHARMACEUTICAL SYNTHESIS

9.1 Atorvastatin

One of the world's best-selling drugs, atorvastatin, has been synthesized via routes employing enzymatic catalysis and greener solvents, reducing waste streams.

9.2 Sitagliptin

Merck's biocatalytic synthesis of sitagliptin replaced rhodium catalysis, increasing productivity while reducing waste and eliminating toxic metals (Tao et al., 2019).

9.3 Artemisinin

Semi-synthetic artemisinin production via engineered yeast showcases renewable feedstock utilization at industrial scale (Calarco et al., 2020).

9.4 Ibuprofen

Modern synthesis employs atom-economical Friedel–Crafts acylation, reducing waste and improving efficiency compared to early multistep processes (Li & Trost, 2020).

These cases illustrate the feasibility and benefits of integrating green chemistry principles into large-scale pharmaceutical synthesis.

10. CHALLENGES AND LIMITATIONS

Despite progress, several challenges hinder widespread adoption of green chemistry in pharmaceuticals:

- **Economic barriers:** High initial investment in green technologies may discourage adoption.
- **Scalability:** Some biocatalytic and continuous-flow methods face technical hurdles when scaled to industrial production (Klapars & Jensen, 2022).
- **Regulatory uncertainty:** Limited guidelines on the use of novel solvents such as ionic liquids pose barriers.
- **Knowledge gaps:** Interdisciplinary expertise is required, but workforce training remains limited (Jiménez-González et al., 2019).

Addressing these barriers requires coordinated efforts between academia, industry, and policymakers.

11. REGULATORY AND POLICY PERSPECTIVES

Regulatory agencies are increasingly supportive of sustainable manufacturing. The U.S. Food and Drug Administration and European Medicines Agency encourage life cycle assessments and continuous manufacturing adoption (Winterton, 2021).

The alignment of pharmaceutical synthesis with the United Nations Sustainable Development Goals (SDGs) further reinforces the importance of green chemistry. Companies adopting greener practices not only gain regulatory advantages but also strengthen public trust and market competitiveness.

12. FUTURE PERSPECTIVES

The future of green pharmaceutical synthesis lies at the intersection of chemistry, biology, and digital technologies. Synthetic biology and metabolic engineering will expand renewable feedstock use. Artificial intelligence and automation will streamline retrosynthetic planning and process optimization (Andraos, 2021).

Integration of green chemistry with precision medicine and nanotechnology will further demand scalable, efficient, and eco-friendly synthesis routes. As industries commit to carbon neutrality, circular economy models and waste valorization will become central to drug manufacturing.

13. CONCLUSION

Green chemistry has redefined pharmaceutical synthesis by offering strategies that minimize waste, enhance efficiency, and promote sustainability. Advances in catalysis, solvent design, continuous-flow processing, renewable feedstocks, and computational tools demonstrate the feasibility of sustainable drug development. Case studies such as sitagliptin and artemisinin highlight industrial adoption and success. While challenges remain in cost, scalability, and regulation, the trajectory is clear: green chemistry is essential for the future of pharmaceuticals. The integration of these principles not only safeguards the environment but also ensures economic competitiveness and patient safety. Sustainable drug development will increasingly rely on green chemistry as its foundation.

ACKNOWLEDGMENTS

The gratitude goes to the Kebbi State University of Science and Technology, Aliero and Nigeria TETFund for supporting related doctoral research

REFERENCES

1. Anastas, P. T., & Eghbali, N. (2018). Green chemistry: Principles and practice. *Chemical Society Reviews, 47*(16), 5319–5331. https://doi.org/10.1039/C8CS00001H
2. Andraos, J. (2021). Metrics for green chemistry: Applications in pharmaceutical synthesis. *Green Chemistry Letters and Reviews, 14*(2), 176–192. https://doi.org/10.1080/17518253.2021.1903504
3. Calarco, V., Iborra, S., & Corma, A. (2020). Renewable feedstocks in the production of pharmaceuticals. *Nature Reviews Chemistry, 4*(4), 259–276. https://doi.org/10.1038/s41570-020-0182-3
4. Gawande, M. B., Monga, Y., Zboril, R., & Varma, R. S. (2020). Sustainable synthesis of pharmaceuticals using flow chemistry. *ACS Sustainable Chemistry & Engineering, 8*(1), 585–606. https://doi.org/10.1021/acssuschemeng.9b06254
5. Jiménez-González, C., Poechlauer, P., Broxterman, Q. B., Yang, B. S., Am Ende, D. J., Baird, J., Bertsch, C., Hannah, R. E., Dell'Orco, P., Noorman, H., Yee, S., & Kopach, M. E. (2019). Key green engineering research areas for sustainable manufacturing: A perspective from pharmaceutical and fine chemicals manufacturers. *Organic Process Research & Development, 23*(5), 900–911. https://doi.org/10.1021/acs.oprd.9b00066
6. Klapars, A., & Jensen, K. F. (2022). Continuous flow chemistry in drug development: Industrial case studies. *Accounts of Chemical Research, 55*(2), 276–288. https://doi.org/10.1021/acs.accounts.1c00619
7. Kumar, R., & Singh, A. (2021). Biocatalysis in pharmaceutical industry: Green chemistry perspective. *Current Opinion in Green and Sustainable Chemistry, 30*, 100482. https://doi.org/10.1016/j.cogsc.2021.100482
8. Li, C. J., & Trost, B. M. (2020). Atom economy in organic synthesis and pharmaceutical applications. *Proceedings of the National Academy of Sciences, 117*(1), 52–59. https://doi.org/10.1073/pnas.1912756117
9. Poliakoff, M., Licence, P., & George, M. W. (2019). Supercritical fluids in green chemistry and drug development. *Green Chemistry, 21*(8), 1890–1905. https://doi.org/10.1039/C9GC00145C
10. Tao, J., Lin, G., & Liese, A. (2019). Enzyme catalysis for sustainable pharmaceutical production. *Biotechnology Advances, 37*(5), 107403. https://doi.org/10.1016/j.biotechadv.2019.04.008
11. Winterton, N. (2021). Sustainability in pharmaceutical manufacturing. *Nature Reviews Chemistry, 5*(1), 2–3. https://doi.org/10.1038/s41570-020-00227-y